Exelixis, Inc. (EXEL)
54.28
-0.17
(-0.31%)
USD |
NASDAQ |
Aug 31, 12:00
Exelixis Cash from Operations (Annual) : 884.27M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 884.27M |
| December 31, 2024 | 699.97M |
| December 31, 2023 | 333.32M |
| December 31, 2022 | 362.61M |
| December 31, 2021 | 400.80M |
| December 31, 2020 | 208.98M |
| December 31, 2019 | 526.96M |
| December 31, 2018 | 415.72M |
| December 31, 2017 | 165.61M |
| December 31, 2016 | 210.40M |
| December 31, 2015 | -141.58M |
| December 31, 2014 | -235.40M |
| December 31, 2013 | -198.77M |
| December 31, 2012 | -123.15M |
| December 31, 2011 | -159.23M |
| Date | Value |
|---|---|
| December 31, 2010 | -101.05M |
| December 31, 2009 | -14.59M |
| December 31, 2008 | -9.757M |
| December 31, 2007 | -68.74M |
| December 31, 2006 | -45.34M |
| December 31, 2005 | -46.36M |
| December 31, 2004 | -93.84M |
| December 31, 2003 | -79.24M |
| December 31, 2002 | -30.92M |
| December 31, 2001 | -23.77M |
| December 31, 2000 | -12.87M |
| December 31, 1999 | -7.322M |
| December 31, 1998 | -12.73M |
| December 31, 1997 | -10.76M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 524.08M |
| BioMarin Pharmaceutical, Inc. | 827.99M |
| Cytokinetics, Inc. | -510.01M |
| Emergent BioSolutions, Inc. | 170.60M |
| Gilead Sciences, Inc. | 10.02B |